Haemonetics Corporation (HAE)

Debt-to-capital ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Long-term debt	US$ in thousands	797,564	856,849	748,662	751,381	754,102	756,826	759,552	763,141	559,441	633,118	698,043	767,345	690,592	292,721	297,016	296,893	305,513	309,738	313,984	318,144
Total stockholders’ equity	US$ in thousands	959,959	943,319	893,660	864,616	817,997	775,979	729,009	770,423	749,424	730,775	698,549	677,080	731,670	719,152	667,923	608,569	587,109	574,580	583,754	590,966
Debt-to-capital ratio		0.45	0.48	0.46	0.46	0.48	0.49	0.51	0.50	0.43	0.46	0.50	0.53	0.49	0.29	0.31	0.33	0.34	0.35	0.35	0.35

March 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $797,564K ÷ ($797,564K + $959,959K)
= 0.45

The debt-to-capital ratio of Haemonetics Corporation has fluctuated over the periods provided, ranging from a low of 0.29 to a high of 0.53. Generally, the ratio has shown a tendency to vary around the mid-0.4 range. This indicates that, on average, around 40-50% of the company's capital structure is financed by debt, with the remainder coming from equity.

It is worth noting that the ratio has experienced some volatility, with fluctuations potentially reflecting changes in the company's debt levels relative to its total capital. A lower ratio typically suggests a lower level of financial risk, as it indicates that the company relies less on debt financing. Conversely, a higher ratio may imply higher financial risk due to a larger proportion of debt in the capital structure.

Overall, it would be essential to monitor the trend in the debt-to-capital ratio over time to assess Haemonetics Corporation's evolving financial leverage and risk profile.